Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ha44 0.74% w/w · 1 trial · 1 indication
Clinically significant changes in Physical Examinations, vital signs, safety laboratory tests and assessments of scalp and eye irritation and Electrocardiogram. The frequency and severity of Adverse Events.
| Arm | Type | Description |
|---|---|---|
| Ha44 Gel 0.74% w/w | EXPERIMENTAL | Open label, one arm |
| Name | Type | Description |
|---|---|---|
| Ha44 Gel 0.74% w/w | DRUG | HA44 Gel 0.74% comprises of Abametapir as the active pharmaceutical ingredient and Benzyl Alcohol as one of the excipients. |
Inclusion Criteria: 1. Male or female, 6months \< 3years of age 2. Good health 3. Active head lice infestation defined as the presence of at least 3 live lice 4. Dermatological condition of scalp (at least G2 erythema or pruritus with evidence of excoriation/inflammation) 5. Parent/guardian agrees ...
Ha44 0.74% w/w is a small molecule drug being developed for the treatment of head lice infestation. It is administered topically as a gel. The drug is currently in Phase 2 clinical development and is being studied for use in pediatric patients.
Ha44 0.74% w/w is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker symbol RDY. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in patients with head lice infestation.
Ha44 0.74% w/w is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed to assess its safety and pharmacokinetics in pediatric patients with head lice infestation.
Ha44 0.74% w/w has one completed clinical trial, identified as NCT02010333. This was a Phase 2 study titled 'A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice Infestation.' The trial enrolled 22 participants in the United States and included children as young as 6 months.
Ha44 0.74% w/w is a small molecule drug applied topically as a gel for the treatment of head lice infestation. Its specific molecular target has not been disclosed in available information, so the exact mechanism of action is not detailed here.